Every S-3 that NeOnc Technologies Holdings, Inc. (NTHI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow NTHI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTHI filings page.
NeOnc Technologies Holdings, Inc. is registering 555,554 shares of Common Stock for resale by a selling stockholder, consisting of 277,777 issued shares and 277,777 shares issuable upon exercise of a five-year Warrant. The Company will not receive proceeds from resales; proceeds only arise if the Warrant is exercised for cash.
The prospectus states 25,933,365 shares outstanding as of June 12, 2026 and cites a last reported Nasdaq sale price of $4.75 per share as of June 12, 2026. The resale registration covers shares issued under a private placement and the related Warrant with a $9.00 initial exercise price and beneficial ownership exercise limits (4.99%/9.99%).
NeOnc Technologies Holdings, Inc. is registering 680,558 shares of Common Stock for resale by selling stockholders, consisting of 340,279 issued shares and 340,279 shares issuable upon exercise of warrants. The registration covers resales by holders who acquired shares and five-year warrants in private placements in January–March 2026. The Company will not receive proceeds from resales; it may receive exercise proceeds if warrants are exercised. Shares outstanding were 24,911,482 as of April 8, 2026. The prospectus discloses outstanding warrants to purchase 1,815,528 shares exercisable at $9.00 per share and notes recent operating losses and tax liabilities.
NeOnc Technologies Holdings, Inc. filed a shelf registration to offer up to $300,000,000 of securities. The shelf prospectus registers a mix of Common Stock, Preferred Stock, Debt Securities, Warrants, Rights and Units for sale from time to time. The prospectus is a general description; each offering will be described in a prospectus supplement that will state the specific terms, price and net proceeds.
The document discloses clinical-stage operations focused on brain-localized malignancies and two lead product candidates, NEO100 (intranasal) and NEO212 (oral and planned intranasal development). It reports total revenue of $122,990 for 2023–2025, a net loss of $62,146,210 in 2025, and an accumulated deficit of $112,754,655 as of December 31, 2025.